At a glance
ClinicalIndex Comparison RecordPhase 2Active· 23 enrolled
Drug / intervention
Rituximab +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of Rituximab/Bendamustine Followed by Rituximab/Cytarabine for Untreated Mantle Cell Lymphoma
In Brief
A Phase 2 clinical trial evaluating Rituximab, Bendamustine, and 1 other intervention for Mantle Cell Lymphoma. Active but no longer recruiting, targeting 23 participants across 1 site.
Detailed Summary
Mantle cell lymphoma (MCL) is not curable with conventional therapy. This study sought to improve upon standard of care in newly diagnosed, untreated MCL patients who were transplant-eligible using drugs already established as active in MCL. The combination of Rituximab-Bendamustine followed by Rituximab-Cytarabine (RB/RC) was expected to maximize pre-ASCT complete response (CR) rate compared to historical rates approximating 55% with tolerable toxicity.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMantle Cell Lymphoma
CountriesUnited States
CollaboratorsBeth Israel Deaconess Medical Center
Timeline
Phase 2Active
201320142015201620172018201920202021202220232024202520262027202820292030
First PostedAug 2012
Enrollment StartAug 2012
Primary CompletionFeb 2015
TodayJul 2026
Study CompletionApr 2030
First PostedAug 10, 2012
Enrollment StartAug 16, 2012
Primary CompletionFeb 1, 2015
Study CompletionApr 1, 2030
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 13.9 years ago
Interventions
Rituximabdrug
Bendamustinedrug
Cytarabinedrug